Mendra Therapeutics launched with 82 million dollars in Series A funding to modernize rare disease d...

Mendra Therapeutics launched with 82 million dollars in Series A funding to modernize rare disease drug development through AI. Led by BioMarin and Palantir veterans, the startup applies data science to solve patient identification and clinical enrollment hurdles. This signals a systemic shift toward AI-native commercialization in orphan drug markets. By optimizing the entire development lifecycle, Mendra is positioning to overcome the high costs of reaching niche populations. 🧬 #AI #Biotech #Innovation #Funding